Johnson & Johnson reported data showing a Darzalex (daratumumab) plus Tecvayli (teclistamab) combination improved survival metrics in multiple myeloma patients, supporting use of dual‑targeting antibody approaches earlier in therapy. The company framed the result as a potential advance for T‑cell engager strategies that have so far been used in later lines. J&J’s announcement follows a broader industry push to move bispecifics and T‑cell engagers into earlier treatment settings, where depth and durability of response may yield greater long‑term benefit. Detailed subgroup analyses and safety data will determine how broadly the regimen can be adopted and whether it changes standard‑of‑care sequencing. The data also feed competition dynamics: other firms developing bispecifics and antibody‑drug combinations will re‑evaluate trial designs and positioning if survival gains are reproducible across datasets.